Role of prolactin in chloro-S-triazine rat mammary tumorigenesis.
Chloro-S-triazine herbicides [cyanazine (CZ), atrazine (AZ), simazine (SZ)] increase mammary tumors in Crl:CD BR rats but not in F-344 rats or in mice. A nongenotoxic mechanism was investigated since the chloro-S-triazines are negative in short-term tests for genotoxicity. An in vivo battery was used to assess the chloro-S-triazines for estrogenic activity or for their ability to increase prolactin (PRL) levels, both of which play important roles in enhancing mammary gland tumorigenesis in rodents. Ovariectomized (OVX) female rats were treated with AZ, CZ, SZ, or three CZ metabolites for 4 days via intraperitoneal injection. The pattern of responses between the chloro-S-triazines and four controls (estradiol, estriol, haloperidol, reserpine) was compared. For the 6 end-points examined, the responses from rats treated with AZ, CZ, SZ, and the metabolites of CZ most closely matched the responses from the reserpine-treated rats (a PRL rather than estrogenic mechanism). In addition, AZ, CZ, and SZ were tested in several other in vitro models (estrogen/biogenic amine receptor competition assays and a yeast-expressed human estrogen receptor transcription assay) as well as an in vivo 24 h time-course experiment to characterize the CZ-induced increases in PRL levels. AZ, CZ, and SZ are not estrogen receptor (ER) activating compounds based on yeast transactivation and receptor competition data. CZ and AZ demonstrated marginal competition (at mM levels) to the D and alpha2 adrenergic receptors. Ligands to the D2 receptor, but not the alpha2 adrenergic receptor, are known to induce mammary tumors. CZ was also found to produce elevated PRL levels in a time-course similar to that seen with reserpine and haloperidol. Overall, the pattern of responses obtained with the chloro-S-triazines most closely matched the responses observed for reserpine. Taken together, these data suggest chloro-S-triazine-induced mammary tumors in rats are mediated through a PRL mechanism, which is thought to be of low relevance to humans.
O'Connor
J C
JC
DuPont Haskell Laboratory for Toxicology and Industrial Medicine, Newark, DE 19714, USA. john.c.oconnor@usa.dupont.com
Plowchalk
D R
DR
Van Pelt
C S
CS
Davis
L G
LG
Cook
J C
JC
D018759:Adrenergic Uptake Inhibitors / Q000494:pharmacology; D000818:Animals; D001280:Atrazine / Q000378:metabolism / Q000633:toxicity*; D001681:Biological Assay; D001835:Body Weight / Q000187:drug effects; D018492:Dopamine Antagonists / Q000494:pharmacology; D004958:Estradiol / Q000494:pharmacology; D004964:Estriol / Q000494:pharmacology; D005260:Female; D017930:Genes, Reporter; D006220:Haloperidol / Q000494:pharmacology; D006540:Herbicides / Q000378:metabolism / Q000633:toxicity*; D006801:Humans; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced*; D010052:Ovariectomy; D011388:Prolactin / Q000097:blood*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D011960:Receptors, Estrogen / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D012110:Reserpine / Q000494:pharmacology; D012839:Simazine / Q000378:metabolism / Q000633:toxicity*; D015533:Transcriptional Activation; D014227:Triazines / Q000378:metabolism / Q000633:toxicity*; D014599:Uterus / Q000187:drug effects; D015003:Yeasts / Q000235:genetics / Q000378:metabolism
D018759:Adrenergic Uptake Inhibitors; D018492:Dopamine Antagonists; D006540:Herbicides; D011960:Receptors, Estrogen; D014227:Triazines; D004958:Estradiol; D012110:Reserpine; D011388:Prolactin; D004964:Estriol; D006220:Haloperidol; D001280:Atrazine; D012839:Simazine; C007168:cyanazine